Eli Lilly has cheapened from its peak (P/E down from 50x to low 30s), is expected to deliver >30% revenue growth and 50% growth in its dominant obesity platform, and upcoming drug approvals could catalyze further upside.
Vertex was just purchased as the healthcare weighting was increased to 11.7%, reflecting a conviction that healthcare exposure should continue to rise.